The mainstream media is continuing to panic the older population saying more seniors are being hospitalized with the respiratory syncytial virus or RSV, this season. They are also promoting a vaccine for the virus for older adults that will be coming soon.
Pfizer announced on December 7th that the United States Food and Drug Administration would be fast-tracking its review of the company’s experimental vaccine for RSV in people 60 years of age and older, according to a report by WRIC News, an ABC News affiliate out of Richmond.
Expediting a Biologics License Application (BLA) review of the vaccine reduces the standard review period by four months, which would mean that the FDA will make a decision on whether or not it approves the vaccine by May 2023, according to a release from Pfizer. Unfortunately, even with the mainstream media actively covering up the disastrous effects of Pfizer’s COVID “vaccine,” many will be enticed to get injected with the new mRNA cocktail as well.
“With no RSV vaccines currently available, older adults remain at risk for RSV disease and potential severe outcomes, including serious respiratory symptoms, hospitalization, and in some cases, even death,” said Annaliesa Anderson, a senior vice president and chief scientific officer for vaccine research and development at Pfizer.
It’s kind of difficult to believe that anyone has any faith left in Pfizer after their COVID shots have been shown to be deadly in many cases:
“The FDA’s acceptance of the BLA for our RSV vaccine candidate is an important regulatory milestone in Pfizer’s efforts to help protect older adults against RSV and demonstrates additional progress toward what has been an elusive public health goal – reducing the overall burden associated with this infectious disease,” Anderson added.
The FDA will likely approve Pfizer’s “vaccine” and it’ll be the first “vaccine” made to protect against RSV. Maybe it’ll be just as effective as the COVID-19 “vaccine:”